688221 Frontier Biotechnologies Inc.
- 6.06
- -0.34-5.31%
Frontier Biotechnologies Inc. News
Frontier Biotech (688221.SH): Passed pharmaceutical GMP compliance inspection.
On June 3, Gelunhui reported that Frontier Biotech (688221.SH) received the 'Notification of Drug GMP Compliance Inspection Results' (No. 176 of 2024) issued by the Jiangsu Provincial Drug Administration. The freeze-dried powder injection production line located at the company's production base on Zhidao Road in Jiangning District, Nanjing was inspected on-site by the Jiangsu Provincial Drug Administration and found to meet the requirements of the 'Good Manufacturing Practice for Drugs'. The fact that the freeze-dried powder injection production line on Zhidao Road production base passed the drug GMP compliance inspection indicates that this production line meets the requirements of the 'Good Manufacturing Practice for Drugs'. The new production line has been put into operation.
Express News | Frontier Biotech: The freeze-dried powder injection production line has passed the pharmaceutical GMP compliance inspection.
Express News | Qingsong Co., Ltd.: Guangdong Keprui Biotechnology Co., Ltd. related synthetic biotechnology is still in the early stages of development
Frontier Biology (688221) Quarterly Report Review: The year-on-year sales growth rate of innovative domestic HIV drugs is impressive, and deep academic accumulation helps promote products
Incidents. The company announced its 2024 quarterly report. In Q1 2024, the company achieved sales revenue of 24.65 million yuan, a year-on-year increase of 106.93%, net profit attributable to mother - 55.71 million yuan, net profit from non-return to mother - 62.69 million yuan
Frontier Biology (688221): Deepening academic promotion, Aikenin's 24Q1 grew rapidly year-on-year
Incident: The company achieved operating income of 0.25 million yuan (+106.93%) in the first quarter of 2024, achieving net profit of 60 million yuan to mother and net profit of 60 million yuan after deducting non-return to mother. Aikonin increased 75% year-on-year in the first quarter
Frontier Biotech (688221.SH) announced first-quarter results with a net loss of 55.71 million yuan
Frontier Biotech (688221.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Frontier Biological-U (688221) Annual Report Review Report: Domestic HIV Innovative Drug Sales Break 100 Million to Fight AIDS, Open Space for Imagination
incident. The company announces 2023 annual report. In 2023, the company achieved sales revenue of 114 million yuan, an increase of 34.82% over the previous year. Aikonin became the first domestically produced new anti-AIDS drug with annual revenue exceeding 100 million yuan. Company 2023
Frontier Biotech (688221.SH) reported 2023 annual results, with a net loss of 329 million yuan, narrowing the year-on-year loss
Frontier Biotech (688221.SH) released its 2023 annual report. The company achieved operating income of 1 during the reporting period...
Frontier Biology (688221): Iconin's sales exceeded 100 million, and the HIV market capacity continues to expand
Incident: January 22, 2024, Frontier Biotech released its 2023 full-year results forecast. The estimated 2023FY revenue is 110 to 115 million yuan (up 29.81% to 35.71% year-on-year)
Frontier Biotech (688221.SH) issued a forecast loss. The net loss is expected to be about 310 million yuan to a loss of 336 million yuan in 2023
Frontier Biotech (688221.SH) released its 2023 performance forecast. The company expects 2023 to fall under...
Frontier Biology (688221.SH): It has achieved coverage of more than 280 designated HIV treatment hospitals and more than 180 DTP pharmacies in 28 provinces across the country
Gelonghui, January 16 | Frontier Biology (688221.SH) said on the investor interactive platform that the relevant “Medical Community Guidance Opinions” emphasize efforts to further effectively improve the level of primary care services and accelerate the decline in core medical resources. At present, the company has set up a deep and declining marketing network in the field of infectious diseases. By the end of the third quarter of 2023, the company had achieved coverage of more than 280 designated HIV treatment hospitals and more than 180 DTP pharmacies in 28 provinces across the country. It has been included in 29 provinces in the “dual channel” and “slow door” medical insurance catalogue. Empowered by policies, it will help the company further promote channel development
Retail Investors Among Frontier Biotechnologies Inc.'s (SHSE:688221) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 13% Last Week
Key Insights Significant control over Frontier Biotechnologies by retail investors implies that the general public has more power to influence management and governance-related decisions A total of
Frontier Bio-U (688221): Performance growth is in line with expectations, FDA on-site inspection passed
Event: Company announcement of the 2023 three-quarter report. The company achieved revenue of about 72,218,800 yuan in the first three quarters of 2023, an increase of 25.25% over the previous year. Net profit after deducting non-return to the parent in the first three quarters was a loss of 264 million yuan
Frontier Biology (688221): Iconine's revenue increased by more than 25% year on year, and the production quality system passed the FDA inspection with zero defects
Incident: The company released its three-quarter report for 2023, achieving operating income of 72,219 million yuan (+25.3%), net loss attributable to shareholders of the parent company of 240 million yuan (-7.05%), and deductions attributable to shareholders of listed companies
Frontier Biotech (688221.SH) released the first three quarter results, with a net loss of 242 million yuan
Frontier Biotech (688221.SH) disclosed its report for the third quarter of 2023. The company achieved revenue of 72 in the first three quarters...
Frontier Biology (688221.SH): It is proposed to use no more than 960 million yuan of temporarily idle funds raised for cash management
Glonghui September 19: Frontier Biotech (688221.SH) announced that on the premise that it does not affect the normal execution of the company's fund-raising and investment plan, it will manage temporarily idle funds raised in cash. Among them, the maximum cash management amount for funds raised for temporarily idle initial public offerings shall not exceed RMB 900 million. The maximum cash management amount for temporarily idle funds raised by issuing shares to specific targets using simple procedures shall not exceed RMB 60 billion; the maximum amount of use for use is within 12 months from the expiration date of the last authorization period (October 14, 2023) It works. In the foregoing amounts and terms
Frontier Biology (688221.SH): Transactional financial assets are mainly cash management products and income generated
GLONGHUI, September 12丨Frontier Biotech (688221.SH) stated on the investor interactive platform that the company's transactional financial assets are mainly cash management products and revenue generated. Cash management products only invest in products that are highly secure, meet capital protection requirements, and have good liquidity (including but not limited to purchasing capital protected wealth management products, structured deposits, large deposits, term deposits, notification deposits, agreement deposits, etc.).
Frontier Biology (688221): Iconin's Rapid Dosage to Build a Full HIV Treatment Matrix
incident. Company announcement 2023 mid-year report. The company achieved revenue of about 42,4413 million yuan in the first half of 2023, an increase of 62.20% over the previous year. Net profit for the first half of the year was a loss of 173 million yuan, deducted by Gimu
Frontier Biology (688221): Exclusive variety Iconin, rapid revenue growth, “academic+channel+access” three-wheel drive anti-HIV business development
Incident: The company released its semi-annual report for 2023, achieved operating income of 42.441 million yuan (+62.2%), net loss attributable to shareholders of the parent company of 170 million yuan (-40.4%), and deductions attributable to shareholders of the listed company
Frontier Biology (688221.SH) announced semi-annual results, with a net loss of 173 million yuan
Frontier Biology (688221.SH) disclosed the 2023 semi-annual report. The company achieved revenue of 4244 during the reporting period...
Analysis
Price Target
No Data
